FRA:5HZ1 (China)
Â
Class H
€
4.16
+0.20 (+5.05%)
Jul 14
Business Description
Hangzhou Tigermed Consulting Co Ltd
ISIN : CNE1000040M1
Share Class Description:
FRA:5HZ1: Class HTotal Employee Number:
11,130Compare
Compare
Traded in other countries / regions
300347.China03347.Hong Kong5HZ1.GermanyHNGZY.USA IPO Date
2021-06-16Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.28 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 1.56 | |||||
Interest Coverage | 9.26 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.04 | |||||
Beneish M-Score | -2.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.8 | |||||
3-Year EBITDA Growth Rate | -21.1 | |||||
3-Year EPS without NRI Growth Rate | -38.2 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | 2.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.38 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.19 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.79 | |||||
9-Day RSI | 67.67 | |||||
14-Day RSI | 63.82 | |||||
3-1 Month Momentum % | -23.71 | |||||
6-1 Month Momentum % | -37.89 | |||||
12-1 Month Momentum % | -31.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.3 | |||||
Quick Ratio | 2.28 | |||||
Cash Ratio | 0.76 | |||||
Days Inventory | 3.12 | |||||
Days Sales Outstanding | 68.52 | |||||
Days Payable | 23.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.41 | |||||
Dividend Payout Ratio | 0.49 | |||||
3-Year Dividend Growth Rate | -15.7 | |||||
Forward Dividend Yield % | 0.41 | |||||
5-Year Yield-on-Cost % | 0.58 | |||||
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 4.02 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 26.64 | |||||
Operating Margin % | 9.61 | |||||
Net Margin % | 10.91 | |||||
EBITDA Margin % | 15.65 | |||||
FCF Margin % | 14.45 | |||||
OCF Margin % | 17.51 | |||||
ROE % | 3.71 | |||||
ROA % | 2.69 | |||||
ROIC % | 2.12 | |||||
3-Year ROIIC % | -17.18 | |||||
ROC (Joel Greenblatt) % | 66.13 | |||||
ROCE % | 4.34 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 57.03 | |||||
Forward PE Ratio | 22.75 | |||||
PE Ratio without NRI | 84.8 | |||||
Shiller PE Ratio | 35.55 | |||||
Price-to-Owner-Earnings | 87.82 | |||||
PS Ratio | 6.17 | |||||
PB Ratio | 2.14 | |||||
Price-to-Tangible-Book | 2.6 | |||||
Price-to-Free-Cash-Flow | 42.72 | |||||
Price-to-Operating-Cash-Flow | 35.26 | |||||
EV-to-EBIT | 38.98 | |||||
EV-to-Forward-EBIT | 16.72 | |||||
EV-to-EBITDA | 38.98 | |||||
EV-to-Revenue | 6.1 | |||||
EV-to-Forward-Revenue | 6.04 | |||||
EV-to-FCF | 42.23 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 1.52 | |||||
Price-to-Median-PS-Value | 0.53 | |||||
Price-to-Graham-Number | 3.13 | |||||
Earnings Yield (Greenblatt) % | 2.57 | |||||
FCF Yield % | 2.4 | |||||
Forward Rate of Return (Yacktman) % | -30.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hangzhou Tigermed Consulting Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 861.151 | ||
| EPS (TTM) (€) | 0.11 | ||
| Beta | 1.4627 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.03 | ||
| Volatility % | 75.56 | ||
| 14-Day RSI | 63.82 | ||
| 14-Day ATR (€) | 0.137415 | ||
| 20-Day SMA (€) | 3.737 | ||
| 12-1 Month Momentum % | -31.92 | ||
| 52-Week Range (€) | 3.22 - 6.4 | ||
| Shares Outstanding (Mil) | 861.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hangzhou Tigermed Consulting Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hangzhou Tigermed Consulting Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| HKD 0.144680 Cash Dividend | 2026-06-18 | 3.34 (+0.00%) | ||
| HKD 0.324500 Cash Dividend | 2025-06-12 | 4.40 (-1.79%) |
Show
Entries
Hangzhou Tigermed Consulting Co Ltd Frequently Asked Questions
What is Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1)'s stock price today?
The current price of FRA:5HZ1 is €4.16. The 52 week high of FRA:5HZ1 is €6.40 and 52 week low is €3.22.
When is next earnings date of Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1)?
The next earnings date of Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1) is .
Does Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1) pay dividends? If so, how much?
The Dividend Yield %  of Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1) is 0.41% (As of Today), Highest Dividend Payout Ratio of Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1) was 0.71. The lowest was 0.21. And the median was 0.31. The  Forward Dividend Yield % of Hangzhou Tigermed Consulting Co Ltd(FRA:5HZ1) is 0.41%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Tigermed Announces 2025 Annual Results | 2026-03-30 | ||
| Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30 | 2025-11-06 | ||
| Tigermed Receives MSCI ESG AAA Rating | 2025-08-18 | ||
| Tigermed Completes Acquisition of Japanese CRO Micron | 2025-07-29 | ||
| Tigermed Reports Full Year 2024 Results | 2025-03-27 | ||
| Tigermed Reports 2024 Interim Results | 2024-08-28 | ||
| Tigermed Reports Full Year 2023 Results | 2024-03-28 | ||
| Tigermed Reports 2023 Interim Results | 2023-08-25 | ||
| Tigermed Officially Opens International Headquarters in Hong Kong | 2023-08-17 | ||
| Tigermed Officially Opens International Headquarters in Hong Kong | 2023-08-16 |
Articles on Hangzhou Tigermed Consulting Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers